ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
18 Years - 99 Years
Endpoint Classification: -
Intervention Model: Sequential Assignment
Primary Purpose: Treatment
Verified 01 Aug 2023 by AstraZeneca
No locations available
Participants will receive durvalumab.